Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiapatients muststagechemotherapypotential
  Phrases that lowered it: 20hcvhepatitishivhealthy
• Sponsor's past termination rate: 3.0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Sponsor's past trials: 165 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 44 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 17.1% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 74.2% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Drugs with FDA adverse-event history: 7 (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 69 (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 18423 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 77087 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 12 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) NCT01518153 · started 2012 · scored riskier than 88% of active trials terminated
• Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL NCT03524235 · started 2018 · scored riskier than 77% of active trials completed
• Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia NCT02446964 · started 2015 · scored riskier than 80% of active trials completed
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02566304 · started 2015 · scored riskier than 99% of active trials completed
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant NCT01231412 · started 2010 · scored riskier than 49% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.